Literature DB >> 24718373

Dopamine function in cigarette smokers: an [¹⁸F]-DOPA PET study.

Michael A P Bloomfield1, Fiona Pepper1, Alice Egerton1, Arsime Demjaha1, Gianpaolo Tomasi2, Elias Mouchlianitis3, Levi Maximen4, Mattia Veronese5, Federico Turkheimer5, Sudhakar Selvaraj3, Oliver D Howes1.   

Abstract

Tobacco addiction is a global public health problem. Addiction to tobacco is thought to involve the effects of nicotine on the dopaminergic system. Only one study has previously investigated dopamine synthesis capacity in cigarette smokers. This study, exclusively in male volunteers, reported increased dopamine synthesis capacity in heavy smokers compared with non-smokers. We sought to determine whether dopamine synthesis capacity was elevated in a larger sample of cigarette smokers that included females. Dopamine synthesis capacity was measured in 15 daily moderate smokers with 15 sex- and age-matched control subjects who had never smoked tobacco. Dopamine synthesis capacity (indexed as the influx rate constant K(i)(cer)) was measured with positron emission tomography and 3,4-dihydroxy-6-[(18)F]-fluoro-l-phenylalanine. There was no significant group difference in dopamine synthesis capacity between smokers and non-smoker controls in the whole striatum (t28=0.64, p=0.53) or any of its functional subdivisions. In smokers, there were no significant relationships between the number of cigarettes smoked per day and dopamine synthesis capacity in the whole striatum (r=-0.23, p=0.41) or any striatal subdivision. These findings indicate that moderate smoking is not associated with altered striatal dopamine synthesis capacity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24718373      PMCID: PMC4138749          DOI: 10.1038/npp.2014.87

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  59 in total

1.  Multiresolution analysis of emission tomography images in the wavelet domain.

Authors:  F E Turkheimer; M Brett; D Visvikis; V J Cunningham
Journal:  J Cereb Blood Flow Metab       Date:  1999-11       Impact factor: 6.200

2.  Nicotine modulates dopamine synthesis rate as determined by L-[beta-11C]DOPA: PET studies compared with [11C]raclopride binding in the conscious monkey brain.

Authors:  Hideo Tsukada; Katsumasa Miyasato; Norihiro Harada; Shingo Nishiyama; Dai Fukumoto; Takeharu Kakiuchi
Journal:  Synapse       Date:  2005-08       Impact factor: 2.562

3.  Inhibition of monoamine oxidase B in the brains of smokers.

Authors:  J S Fowler; N D Volkow; G J Wang; N Pappas; J Logan; R MacGregor; D Alexoff; C Shea; D Schlyer; A P Wolf; D Warner; I Zezulkova; R Cilento
Journal:  Nature       Date:  1996-02-22       Impact factor: 49.962

4.  Establishing a nicotine threshold for addiction. The implications for tobacco regulation.

Authors:  N L Benowitz; J E Henningfield
Journal:  N Engl J Med       Date:  1994-07-14       Impact factor: 91.245

5.  Smoking and depression: an examination of mechanisms of comorbidity.

Authors:  Lisa C Dierker; Shelli Avenevoli; Marilyn Stolar; K R Merikangas
Journal:  Am J Psychiatry       Date:  2002-06       Impact factor: 18.112

6.  Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal.

Authors:  J C Wu; K Bell; A Najafi; C Widmark; D Keator; C Tang; E Klein; B G Bunney; J Fallon; W E Bunney
Journal:  Neuropsychopharmacology       Date:  1997-12       Impact factor: 7.853

7.  The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases.

Authors:  P Lautala; B T Ethell; J Taskinen; B Burchell
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

8.  Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.

Authors:  M Guttman; G Léger; A Reches; A Evans; H Kuwabara; J M Cedarbaum; A Gjedde
Journal:  Mov Disord       Date:  1993-07       Impact factor: 10.338

9.  Smoking-induced ventral striatum dopamine release.

Authors:  Arthur L Brody; Richard E Olmstead; Edythe D London; Judah Farahi; Jeffrey H Meyer; Paul Grossman; Grace S Lee; Joe Huang; Emily L Hahn; Mark A Mandelkern
Journal:  Am J Psychiatry       Date:  2004-07       Impact factor: 18.112

10.  Elevated striatal dopamine function linked to prodromal signs of schizophrenia.

Authors:  Oliver D Howes; Andrew J Montgomery; Marie-Claude Asselin; Robin M Murray; Isabel Valli; Paul Tabraham; Elvira Bramon-Bosch; Lucia Valmaggia; Louise Johns; Matthew Broome; Philip K McGuire; Paul M Grasby
Journal:  Arch Gen Psychiatry       Date:  2009-01
View more
  21 in total

1.  Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.

Authors:  Euitae Kim; Oliver D Howes; Mattia Veronese; Katherine Beck; Seongho Seo; Jin Woo Park; Jae Sung Lee; Yun-Sang Lee; Jun Soo Kwon
Journal:  Neuropsychopharmacology       Date:  2016-11-18       Impact factor: 7.853

Review 2.  A review of positron emission tomography studies exploring the dopaminergic system in substance use with a focus on tobacco as a co-variate.

Authors:  Thulasi Thiruchselvam; Saima Malik; Bernard Le Foll
Journal:  Am J Drug Alcohol Abuse       Date:  2016-11-30       Impact factor: 3.829

3.  Where There is Smoke There is Fear-Impaired Contextual Inhibition of Conditioned Fear in Smokers.

Authors:  Jan Haaker; Tina B Lonsdorf; Dirk Schümann; Nico Bunzeck; Jan Peters; Tobias Sommer; Raffael Kalisch
Journal:  Neuropsychopharmacology       Date:  2017-01-25       Impact factor: 7.853

4.  The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study.

Authors:  Tarik Dahoun; Antonio F Pardiñas; Mattia Veronese; Michael A P Bloomfield; Sameer Jauhar; Ilaria Bonoldi; Sean Froudist-Walsh; Chiara Nosarti; Carsten Korth; William Hennah; James Walters; Diana Prata; Oliver D Howes
Journal:  Hum Mol Genet       Date:  2018-10-15       Impact factor: 6.150

Review 5.  Neuroimaging of reward mechanisms in Gambling disorder: an integrative review.

Authors:  Luke Clark; Isabelle Boileau; Martin Zack
Journal:  Mol Psychiatry       Date:  2018-09-13       Impact factor: 15.992

6.  Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating.

Authors:  Joonas Majuri; Juho Joutsa; Jarkko Johansson; Valerie Voon; Kati Alakurtti; Riitta Parkkola; Tuuli Lahti; Hannu Alho; Jussi Hirvonen; Eveliina Arponen; Sarita Forsback; Valtteri Kaasinen
Journal:  Neuropsychopharmacology       Date:  2016-11-24       Impact factor: 7.853

7.  A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia.

Authors:  Sameer Jauhar; Matthew M Nour; Mattia Veronese; Maria Rogdaki; Ilaria Bonoldi; Matilda Azis; Federico Turkheimer; Philip McGuire; Allan H Young; Oliver D Howes
Journal:  JAMA Psychiatry       Date:  2017-12-01       Impact factor: 21.596

8.  The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study.

Authors:  Enrico D'Ambrosio; Tarik Dahoun; Antonio F Pardiñas; Mattia Veronese; Michael A P Bloomfield; Sameer Jauhar; Ilaria Bonoldi; Maria Rogdaki; Sean Froudist-Walsh; James T R Walters; Oliver D Howes
Journal:  Psychiatry Res Neuroimaging       Date:  2019-07-19       Impact factor: 2.376

9.  Single cocaine exposure does not alter striatal pre-synaptic dopamine function in mice: an [18 F]-FDOPA PET study.

Authors:  David R Bonsall; Michelle Kokkinou; Mattia Veronese; Christopher Coello; Lisa A Wells; Oliver D Howes
Journal:  J Neurochem       Date:  2017-10-26       Impact factor: 5.372

10.  Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis.

Authors:  Seoyoung Kim; Sang Ho Shin; Barbara Santangelo; Mattia Veronese; Seung Kwan Kang; Jae Sung Lee; Gi Jeong Cheon; Woojoo Lee; Jun Soo Kwon; Oliver D Howes; Euitae Kim
Journal:  Mol Psychiatry       Date:  2020-09-14       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.